Brought to you by 
Mylan at last acquires Meda, paying $9.9bn
10 Sep 2020
Executive Summary
Almost two years after launching two separate (but unsuccessful) hostile bids, Mylan NV is taking over publicly traded Swedish spec pharma Meda AB for SEK83.6bn ($9.9bn). Mylan will pay $8.5bn in cash (SEK165 ($19.68) per share, an 84% premium) and debt, and issue about $1.4bn in Mylan stock). The deal is subject to 90% of Meda shareholders tendering their shares; stakeholders accounting for about 30% of shares have already accepted the offer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan at last acquires Meda, paying $9.9bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice